Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Context Therapeutics Inc. (CNTX)
USD0.63
+0.01 (+1.19%)
US NASDAQ Healthcare Biotechnology
Address
2001 Market Street 19103
Philadelphia, PA, US
Philadelphia, PA, US
CEO
Martin A. Lehr
Website
contexttherapeutics.com
IPO
2021-10-20
CIK 1842952 ISIN US21077P1084
Description
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
News Sentiment (7d)
Based on only 2 articles — low confidence
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.63
+0.01 (+1.19%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
2M
Beta
1.61
Float Shares
65.00M
Free Float %
70.7%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +3.77% | +3.77% | -0.40% | +2.06% | +110.17% | +68.71% | +217.99% | +345.48% | -51.37% | -51.37% | -51.37% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (6 ratings, all time)
Buy
Price Targets & DCF
Current price
0.63
Low
4.50
+613.9%
Consensus
5.25
+732.9%
Median
5.25
+732.9%
High
6.00
+851.9%
DCF (Unlevered)
0.67
+6.0%
DCF (Levered)
0.69
+9.8%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 3 | 0 |
| Buy | 7 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | — | — |
| All Time | 3 |
5.17
+720.2%
|
Quality scores
Altman Z-Score
15.06
Safe zone
Piotroski F-Score
2 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
4 / 5
High
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+17.4% Q1'26: -82.4% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'26: +1,828.7% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+62.9% Q1'26: 0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00× Q1'26: -0.01× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 9 Rev. Ana. 7 EPS Ana. |
Dec 2027 6 EPS Ana. |
Dec 2028 8 Rev. Ana. 8 EPS Ana. |
Dec 2029 7 Rev. Ana. 6 EPS Ana. |
Dec 2030 7 Rev. Ana. 6 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
—
|
—
|
2.00M
2.00M – 2.00M
|
—
— – —
-100.0% YoY
|
9.26M
9.26M – 9.26M
|
37.74M
37.74M – 37.74M
+307.4% YoY
|
108.84M
108.84M – 108.84M
+188.4% YoY
|
| EBITDA |
-29.91M
|
-39.69M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-29.92M
|
-39.70M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-26.73M
est: -34.21M (+21.9%)
|
-36.12M
est: -33.32M (-8.4%)
|
-39.69M
-43.53M – -23.28M
-19.1% YoY
|
-34.94M
-46.91M – -22.97M
+12.0% YoY
|
-57.28M
-73.07M – -936.7K
-63.9% YoY
|
-32.64M
-32.64M – -32.64M
+43.0% YoY
|
-2.38M
-2.38M – -2.38M
+92.7% YoY
|
| SGA |
7.22M
|
7.85M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-0.46
est: -0.58 (+20.7%)
|
-0.38
est: -0.35 (-8.5%)
|
-0.37
-0.46 – -0.24
-6.3% YoY
|
-0.39
-0.49 – -0.24
-5.4% YoY
|
-0.47
-0.77 – -0.01
-18.6% YoY
|
-0.34
-0.34 – -0.34
+26.3% YoY
|
-0.03
-0.03 – -0.03
+92.7% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-11 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-08 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-07 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-06 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-05 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-04 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-01 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-30 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-29 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-28 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-27 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-24 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-23 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-17 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-16 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
3
Total invested
19.2K
Insider transactions (90d)
0
Beneficial owners (>5%)
27
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Avidity Private Master Fund I LP | 7.78M | 9.90% | — | 7.78M | — | 7.78M | PN, OO | Delaware | 2024-05-13 | ↗ |
| 2 | Avidity Capital Partners (GP) LLC | 7.50M | 9.90% | — | 7.50M | — | 7.50M | OO | Delaware | 2024-05-13 | ↗ |
| 3 | Avidity Capital Partners Fund (GP) LP | 7.50M | 9.90% | — | 7.50M | — | 7.50M | PN, OO | Delaware | 2024-05-13 | ↗ |
| 4 | Avidity Partners Management (GP) LLC | 7.50M | 9.90% | — | 7.50M | — | 7.50M | OO | Delaware | 2024-05-13 | ↗ |
| 5 | Avidity Partners Management LP | 7.50M | 9.90% | — | 7.50M | — | 7.50M | IA, PN | Delaware | 2024-05-13 | ↗ |
| 6 | David Witzke | 7.50M | 9.90% | — | 7.50M | — | 7.50M | IN | Delaware | 2024-05-13 | ↗ |
| 7 | Michael Gregory | 7.50M | 9.90% | — | 7.50M | — | 7.50M | IN | Delaware | 2024-05-13 | ↗ |
| 8 | Costas Constantinides | 7.42M | 9.90% | — | 7.42M | — | — | IN | Luxembourg | 2024-05-24 | ↗ |
| 9 | Ian Charoub | 7.42M | 9.90% | — | 7.42M | — | — | IN | Luxembourg | 2024-05-24 | ↗ |
| 10 | Nextech Crossover I GP S.à r.l. | 7.42M | 9.90% | 7.42M | — | 7.42M | — | OO | Luxembourg | 2024-05-24 | ↗ |
| 11 | Nextech Crossover I SCSp | 7.42M | 9.90% | 7.42M | — | 7.42M | — | PN | Luxembourg | 2024-05-24 | ↗ |
| 12 | Rocco Sgobbo | 7.42M | 9.90% | — | 7.42M | — | — | IN | Luxembourg | 2024-05-24 | ↗ |
| 13 | David Kroin | 7.42M | 9.89% | — | 7.42M | — | — | HC, IN | Delaware | 2024-05-10 | ↗ |
| 14 | Deep Track Biotechnology Master Fund, Ltd. | 7.42M | 9.89% | — | 7.42M | — | — | CO | Delaware | 2024-05-10 | ↗ |
| 15 | Deep Track Capital, LP | 7.42M | 9.89% | — | 7.42M | — | — | IA, OO | Delaware | 2024-05-10 | ↗ |
| 16 | Dr. Jeffrey R. Jay, M.D. | 7.42M | 9.89% | — | 7.42M | — | — | HC, IN | Delaware | 2024-06-05 | ↗ |
| 17 | Great Point Partners, LLC | 7.42M | 9.89% | — | 7.42M | — | — | IA, OO | Delaware | 2024-06-05 | ↗ |
| 18 | Mr. Ortav Yehudai | 7.42M | 9.89% | — | 7.42M | — | — | HC, IN | USA | 2024-06-05 | ↗ |
| 19 | Blue Owl Capital Holdings LP | 5.41M | 7.22% | 5.41M | — | 5.41M | — | PN | Delaware | 2024-11-14 | ↗ |
| 20 | Avidity Master Fund LP | 5.13M | 6.60% | — | 5.13M | — | 5.13M | PN, OO | Delaware | 2024-05-13 | ↗ |
| 21 | 27-4413262 | 1.29M | 8.10% | 1.29M | — | 1.29M | — | OO | Maryland | 2022-10-27 | ↗ |
| 22 | Identification Nos. of above persons (. | 1.29M | 8.10% | 1.29M | — | 1.29M | — | IN | Maryland | 2022-10-27 | ↗ |
| 23 | Martin Lehr | 1.19M | 7.30% | 365.9K | 820.2K | 365.9K | — | IN | United States | 2023-02-14 | ↗ |
| 24 | Affinity Healthcare Fund, LP (EIN 82-1629802) | 883.7K | 5.53% | — | 883.7K | — | 883.7K | PN | — | 2022-05-09 | ↗ |
| 25 | Ellyn Lehr | 820.2K | 5.10% | — | 820.2K | — | — | IN | Pennsylvania | 2023-02-14 | ↗ |
| 26 | Martin Lehr 2000 Trust | 820.2K | 5.10% | — | 820.2K | — | — | OO | Pennsylvania | 2023-02-14 | ↗ |
| 27 | Opaleye Management Inc. | 820.0K | 5.14% | — | 8.20M | — | 820.0K | CO | Massachusetts | 2024-01-05 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
3
-39 vs prev Q
New positions
1
Closed positions
40
Increased
1
Reduced
1
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | BIOIMPACT CAPITAL LLC | 10.68M -4.0M (-27.4%) | 15.70M +1.5M (+10.2%) | 11.22% -4.230 pp | 1.80% -0.536 pp | USD1.05 +40.0% | 5 qtrs — |
| 2 | BLUE OWL CAPITAL HOLDINGS LP | 7.43M +25.0K (+0.3%) | 10.93M +3.7M (+52.2%) | 7.81% +0.026 pp | 0.82% -1.410 pp | USD1.55 -5.2% | 7 qtrs — |
| 3 | NEXTECH INVEST, LTD. | 7.42M +— (+0.0%) | 10.91M +3.7M (+51.7%) | 7.79% +0.000 pp | 1.05% -0.040 pp | USD0.61 +141.0% | 4 qtrs — |
| 4 | DEEP TRACK CAPITAL, LP | 7.42M +— (+0.0%) | 10.91M +3.7M (+51.7%) | 7.79% +0.000 pp | 0.19% -0.006 pp | USD1.81 -18.8% | 7 qtrs — |
| 5 | AVIDITY PARTNERS MANAGEMENT LP | 5.50M -3.5M (-38.7%) | 8.09M -609.5K (-7.0%) | 5.78% -3.653 pp | 2.33% +0.354 pp | USD1.66 -11.4% | 7 qtrs — |
| 6 | GREAT POINT PARTNERS LLC | 4.68M +— (+0.0%) | 6.89M +2.3M (+51.7%) | 4.92% +0.000 pp | 2.23% +0.361 pp | USD1.81 -18.8% | 7 qtrs — |
| 7 | FRANKLIN RESOURCES INC | 4.00M +— (+0.0%) | 5.88M +2.0M (+51.7%) | 4.21% +0.000 pp | 0.00% +0.001 pp | USD1.47 +0.0% | 6 qtrs — |
| 8 | VANGUARD GROUP INC | 3.79M +290.9K (+8.3%) | 5.57M +2.2M (+64.3%) | 3.98% +0.306 pp | 0.00% +0.000 pp | USD1.77 -16.9% | 17 qtrs — |
| 9 | MILLENNIUM MANAGEMENT LLC | 2.60M +2.6M (+100.0%) | 3.82M +3.8M (+100.0%) | 2.73% +2.733 pp | 0.00% +0.002 pp | USD1.47 +0.0% | 6 qtrs — |
| 10 | MARSHALL WACE, LLP | 2.59M +2.6M (+7,153.7%) | 3.81M +3.8M (+10,892.6%) | 2.72% +2.687 pp | 0.00% +0.003 pp | USD1.46 +0.7% | 2 qtrs — |
| 11 | BLACKSTONE INC. | 2.44M +— (+0.0%) | 3.59M +1.2M (+51.7%) | 2.56% +0.000 pp | 0.01% +0.005 pp | USD1.85 -20.5% | 7 qtrs — |
| 12 | ALYESKA INVESTMENT GROUP, L.P. | 1.66M +— (+0.0%) | 2.45M +833.7K (+51.7%) | 1.75% +0.000 pp | 0.01% +0.002 pp | USD1.81 -18.8% | 7 qtrs — |
| 13 | SIO CAPITAL MANAGEMENT, LLC | 1.34M +— (+0.0%) | 1.97M +672.4K (+51.7%) | 1.41% +0.000 pp | 0.31% -0.019 pp | USD1.80 -18.3% | 7 qtrs — |
| 14 | BLACKROCK, INC. | 848.0K -924.0 (-0.1%) | 1.25M +424.1K (+51.6%) | 0.89% -0.001 pp | 0.00% +0.000 pp | USD1.90 -22.6% | 6 qtrs — |
| 15 | GEODE CAPITAL MANAGEMENT, LLC | 608.5K -115.0 (0.0%) | 894.9K +305.0K (+51.7%) | 0.64% 0.000 pp | 0.00% +0.000 pp | USD1.73 -15.0% | 16 qtrs — |
| 16 | RENAISSANCE TECHNOLOGIES LLC | 508.3K +188.2K (+58.8%) | 747.2K +437.1K (+140.9%) | 0.53% +0.198 pp | 0.00% +0.001 pp | USD1.19 +23.5% | 17 qtrs — |
| 17 | ADAR1 CAPITAL MANAGEMENT, LLC | 351.1K +— (+0.0%) | 516.1K +176.0K (+51.7%) | 0.37% +0.000 pp | 0.04% +0.006 pp | USD1.67 -12.0% | 8 qtrs — |
| 18 | STATE STREET CORP | 165.6K +13.0K (+8.5%) | 243.4K +95.6K (+64.7%) | 0.17% +0.014 pp | 0.00% +0.000 pp | USD1.59 -7.5% | 15 qtrs — |
| 19 | WALLEYE CAPITAL LLC | 132.8K +— (+0.0%) | 195.2K +66.6K (+51.7%) | 0.14% +0.000 pp | 0.00% +0.000 pp | USD1.54 -4.5% | 7 qtrs — |
| 20 | HIGHTOWER ADVISORS, LLC | 125.9K +— (+0.0%) | 185.0K +63.1K (+51.7%) | 0.13% +0.000 pp | 0.00% +0.000 pp | USD2.12 -30.7% | 15 qtrs — |
| 21 | PATHSTONE HOLDINGS, LLC | 110.2K +— (+0.0%) | 162.1K +55.3K (+51.7%) | 0.12% +0.000 pp | 0.00% +0.000 pp | USD0.97 +51.5% | 2 qtrs — |
| 22 | MILL CREEK CAPITAL ADVISORS, LLC | 104.6K +— (+0.0%) | 153.8K +52.4K (+51.7%) | 0.11% +0.000 pp | 0.00% +0.001 pp | USD0.66 +122.7% | 13 qtrs — |
| 23 | XTX TOPCO LTD | 101.6K +91.0K (+858.8%) | 149.4K +139.1K (+1,354.9%) | 0.11% +0.096 pp | 0.00% +0.003 pp | USD1.42 +3.5% | 4 qtrs — |
| 24 | VELAN CAPITAL INVESTMENT MANAGEMENT LP | 100.0K +— (+0.0%) | 147.0K +50.1K (+51.7%) | 0.11% +0.000 pp | 0.09% -0.006 pp | USD1.69 -13.0% | 7 qtrs — |
| 25 | CLEAR HARBOR ASSET MANAGEMENT, LLC | 92.8K +— (+0.0%) | 136.4K +46.5K (+51.7%) | 0.10% +0.000 pp | 0.01% +0.004 pp | USD1.23 +19.5% | 11 qtrs — |
| 26 | NORTHERN TRUST CORP | 84.3K +17.9K (+27.0%) | 123.9K +59.6K (+92.6%) | 0.09% +0.019 pp | 0.00% +0.000 pp | USD1.70 -13.5% | 15 qtrs — |
| 27 | POINT72 ASSET MANAGEMENT, L.P. | 52.7K +52.7K (+100.0%) | 77.5K +77.5K (+100.0%) | 0.06% +0.055 pp | 0.00% +0.000 pp | USD1.47 +0.0% | 1 qtrs NEW |
| 28 | QUADRATURE CAPITAL LTD | 46.2K +46.2K (+100.0%) | 67.9K +67.9K (+100.0%) | 0.05% +0.049 pp | 0.00% +0.001 pp | USD1.47 +0.0% | 1 qtrs NEW |
| 29 | NANTAHALA CAPITAL MANAGEMENT, LLC | 37.8K -1.6M (-97.7%) | 55.6K -1.6M (-96.5%) | 0.04% -1.706 pp | 0.00% -0.054 pp | USD1.81 -18.8% | 7 qtrs — |
| 30 | CITADEL ADVISORS LLC | 34.4K -69.0K (-66.7%) | 50.5K -49.6K (-49.5%) | 0.04% -0.073 pp | 0.00% +0.000 pp | USD0.97 +51.5% | 2 qtrs — |
| 31 | VIRTU FINANCIAL LLC | 28.9K +28.9K (+100.0%) | 43.0K +43.0K (+100.0%) | 0.03% +0.030 pp | 0.00% +0.002 pp | USD1.47 +0.0% | 1 qtrs NEW |
| 32 | ADVISOR GROUP HOLDINGS, INC. | 25.5K +— (+0.0%) | 37.5K +12.9K (+52.3%) | 0.03% +0.000 pp | 0.00% +0.000 pp | USD1.00 +47.0% | 11 qtrs — |
| 33 | CERITY PARTNERS LLC | 20.0K +— (+0.0%) | 29.4K +10.0K (+51.7%) | 0.02% +0.000 pp | 0.00% +0.000 pp | USD1.31 +12.2% | 6 qtrs — |
| 34 | CAXTON CORP | 18.4K +— (+0.0%) | 27.1K +9.2K (+51.7%) | 0.02% +0.000 pp | 0.63% +0.554 pp | USD1.81 -18.8% | 7 qtrs — |
| 35 | CI PRIVATE WEALTH, LLC | 15.1K +15.1K (+100.0%) | 22.2K +22.2K (+100.0%) | 0.02% +0.016 pp | 0.00% +0.000 pp | USD1.47 +0.0% | 1 qtrs NEW |
| 36 | TOWER RESEARCH CAPITAL LLC (TRC) | 9.6K +9.6K (+100.0%) | 14.1K +14.1K (+100.0%) | 0.01% +0.010 pp | 0.00% +0.000 pp | USD1.47 +0.0% | 17 qtrs — |
| 37 | — | 1.7K +1.7K (+100.0%) | 2.5K +2.5K (+100.0%) | 0.00% +0.002 pp | 0.00% +0.001 pp | USD1.47 +0.0% | 1 qtrs NEW |
| 38 | FARTHER FINANCE ADVISORS, LLC | 1.5K +1.5K (+100.0%) | 2.2K +2.2K (+100.0%) | 0.00% +0.002 pp | 0.00% +0.000 pp | USD1.47 +0.0% | 1 qtrs NEW |
| 39 | CITIGROUP INC | 1.3K +1.3K (+100.0%) | 2.0K +2.0K (+100.0%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD1.47 +0.0% | 1 qtrs NEW |
| 40 | BANK OF AMERICA CORP /DE/ | 933.00 +499.0 (+115.0%) | 1.4K +951.0 (+226.4%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD1.53 -3.9% | 13 qtrs — |
| 41 | UBS GROUP AG | 490.00 -6.9K (-93.4%) | 720.00 -6.4K (-89.9%) | 0.00% -0.007 pp | 0.00% +0.000 pp | USD0.97 +51.5% | 6 qtrs — |
| 42 | SBI SECURITIES CO., LTD. | 114.00 -3.0 (-2.6%) | 168.00 +55.0 (+48.7%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.03 +42.7% | 5 qtrs — |
| 43 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | — -22.0K (-100.0%) | — -21.3K (-100.0%) | 0.00% -0.023 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 44 | QUBE RESEARCH & TECHNOLOGIES LTD | — -82.1K (-100.0%) | — -79.5K (-100.0%) | 0.00% -0.086 pp | 0.00% 0.000 pp | USD— | 6 qtrs SOLD |
| 45 | AFFINITY ASSET ADVISORS, LLC | — -402.7K (-100.0%) | — -390.1K (-100.0%) | 0.00% -0.423 pp | 0.00% -0.034 pp | USD— | 16 qtrs SOLD |
| 46 | BARCLAYS PLC | — -167.0 (-100.0%) | — -162.0 (-100.0%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 33 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares Micro-Cap ETF IWC | 0.01% | 204.4K | 0.60% |
| 2 | iShares Russell 2000 Growth ETF IWO | 0.00% | 572.7K | 0.24% |
| 3 | Global X - Russell 2000 ETF RSSL | 0.00% | 28.4K | 0.08% |
| 4 | Invesco Russell 2000 UCITS ETF RTYS.L | 0.00% | 6.1K | 0.25% |
| 5 | iShares Russell 2000 BuyWrite ETF IWMW | 0.00% | 1.1K | 0.39% |
| 6 | iShares Russell 2000 ETF IWM | 0.00% | 1.55M | 0.19% |
| 7 | iShares U.S. Small Cap Index ETF (CAD-Hedged) XSU.TO | 0.00% | 10.1K | 0.36% |
| 8 | Xtrackers Russell 2000 UCITS ETF 1C XRSU.L | 0.00% | 48.8K | 0.30% |
| 9 | Vanguard Extended Market ETF VXF | 0.00% | 1.45M | 0.05% |
| 10 | ProShares - Ultra Russell2000 UWM | 0.00% | 2.4K | 1.07% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
10
Sells
0
Shares acquired
1.07M
Shares disposed
—
Cash buys
3.00
Cash sales
—
Net activity
+1,069,410
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-02-19 | Minai-Azary Jennifer Lynn | Officer | A-Award | A | Stock Option (right to buy) | 275,000 | 2.32 | 638.0K | 275,000 | D | ↗ |
| 2026-02-19 | Levit Alex C. | Officer | A-Award | A | Stock Option (right to buy) | 270,000 | 2.32 | 626.4K | 270,000 | D | ↗ |
| 2026-02-19 | Lehr Martin A. | Director / Officer | A-Award | A | Stock Option (right to buy) | 815,000 | 2.32 | 1.89M | 815,000 | D | ↗ |
| 2026-02-19 | Chagin Karen Deborah | Officer | A-Award | A | Stock Option (right to buy) | 290,000 | 2.32 | 672.8K | 290,000 | D | ↗ |
| 2025-06-12 | West Linda | Director | A-Award | A | Stock Option (right to buy) | 123,500 | 0.65 | 80.6K | 123,500 | D | ↗ |
| 2025-06-12 | Walker Luke Nathaniel | Director | A-Award | A | Stock Option (right to buy) | 123,500 | 0.65 | 80.6K | 123,500 | D | ↗ |
| 2025-06-12 | Stacey Jennifer Evans | Director | A-Award | A | Stock Option (right to buy) | 123,500 | 0.65 | 80.6K | 123,500 | D | ↗ |
| 2025-06-12 | Smith Karen L. | Director | A-Award | A | Stock Option (right to buy) | 123,500 | 0.65 | 80.6K | 123,500 | D | ↗ |
| 2025-06-12 | Pasternak Andy | Director | A-Award | A | Stock Option (right to buy) | 138,900 | 0.65 | 90.7K | 138,900 | D | ↗ |
| 2025-06-12 | Kantoff Philip W. | Director | A-Award | A | Stock Option (right to buy) | 123,500 | 0.65 | 80.6K | 123,500 | D | ↗ |
| 2025-06-09 | Lehr Martin A. | Director / Officer | P-Purchase | A | Common Stock | 100,000 | 0.70 | 70.1K | 920,190 | I | ↗ |
| 2025-06-09 | Chagin Karen Deborah | Officer | A-Award | A | Stock Option (right to buy) | 153,000 | 0.70 | 107.6K | 153,000 | D | ↗ |
| 2025-06-06 | Minai-Azary Jennifer Lynn | Officer | P-Purchase | A | Common Stock | 40,010 | 0.64 | 25.5K | 80,010 | D | ↗ |
| 2025-06-06 | Levit Alex C. | Officer | P-Purchase | A | Common Stock | 20,000 | 0.58 | 11.5K | 29,000 | D | ↗ |
| 2025-02-13 | Minai-Azary Jennifer Lynn | Officer | A-Award | A | Stock Option (right to buy) | 371,800 | 0.81 | 301.2K | 371,800 | D | ↗ |
| 2025-02-13 | Levit Alex C. | Officer | A-Award | A | Stock Option (right to buy) | 349,900 | 0.81 | 283.4K | 349,900 | D | ↗ |
| 2025-02-13 | Lehr Martin A. | Director / Officer | A-Award | A | Stock Option (right to buy) | 802,700 | 0.81 | 650.2K | 802,700 | D | ↗ |
| 2025-02-13 | Dansky Ullmann Claudio | Officer | A-Award | A | Stock Option (right to buy) | 174,960 | 0.81 | 141.7K | 174,960 | D | ↗ |
| 2025-01-13 | Pasternak Andy | Director | A-Award | A | Stock Option (right to buy) | 20,685 | 1.03 | 21.3K | 20,685 | D | ↗ |
| 2024-09-04 | Walker Luke Nathaniel | Director | A-Award | A | Stock Option (right to buy) | 19,315 | 2.43 | 46.9K | 19,315 | — | ↗ |
| 2024-09-04 | Smith Karen L. | Director | A-Award | A | Stock Option (right to buy) | 19,315 | 2.43 | 46.9K | 19,315 | — | ↗ |
| 2024-08-01 | Dansky Ullmann Claudio | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-06-13 | West Linda | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 1.97 | 49.3K | 25,000 | — | ↗ |
| 2024-06-13 | Stacey Jennifer Evans | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 1.97 | 49.3K | 25,000 | — | ↗ |
| 2024-06-13 | Kantoff Philip W. | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 1.97 | 49.3K | 25,000 | — | ↗ |
| 2024-06-13 | BERMAN RICHARD J | Director | A-Award | A | Stock Option (right to buy) | 50,000 | 1.97 | 98.5K | 50,000 | — | ↗ |
| 2024-03-21 | Minai-Azary Jennifer Lynn | Officer | A-Award | A | Stock Option (right to buy) | 160,115 | 1.07 | 171.3K | 160,115 | — | ↗ |
| 2024-03-21 | Levit Alex C. | Officer | A-Award | A | Stock Option (right to buy) | 153,515 | 1.07 | 164.3K | 153,515 | — | ↗ |
| 2024-03-21 | Lehr Martin A. | Director / Officer | A-Award | A | Stock Option (right to buy) | 291,402 | 1.07 | 311.8K | 291,402 | — | ↗ |
| 2023-05-31 | West Linda | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 0.87 | 21.8K | 25,000 | — | ↗ |
| 2023-05-31 | Stacey Jennifer Evans | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 0.87 | 21.8K | 25,000 | — | ↗ |
| 2023-05-31 | Kantoff Philip W. | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 0.87 | 21.8K | 25,000 | — | ↗ |
| 2023-05-31 | BERMAN RICHARD J | Director | A-Award | A | Stock Option (right to buy) | 50,000 | 0.87 | 43.5K | 50,000 | — | ↗ |
| 2023-02-21 | Lehr Martin A. | Director / Officer | P-Purchase | A | Common Stock | 5,823 | 0.84 | 4.9K | 159,701 | — | ↗ |
| 2023-02-13 | Minai-Azary Jennifer Lynn | Officer | A-Award | A | Stock Option (right to buy) | 158,001 | 0.84 | 132.8K | 158,001 | — | ↗ |
| 2023-02-13 | Levit Alex C. | Officer | A-Award | A | Stock Option (right to buy) | 151,505 | 0.84 | 127.4K | 151,505 | — | ↗ |
| 2023-02-13 | Lehr Martin A. | Director / Officer | A-Award | A | Stock Option (right to buy) | 287,544 | 0.84 | 241.7K | 287,544 | — | ↗ |
| 2023-02-06 | Lehr Martin A. | Director / Officer | P-Purchase | A | Common Stock | 5,040 | 0.97 | 4.9K | 148,272 | — | ↗ |
| 2023-01-30 | Lehr Martin A. | Officer | P-Purchase | A | Common Stock | 7,027 | 0.70 | 4.9K | 143,232 | — | ↗ |
| 2023-01-23 | Lehr Martin A. | Officer | P-Purchase | A | Common Stock | 6,839 | 0.72 | 4.9K | 136,205 | — | ↗ |
| 2023-01-17 | Lehr Martin A. | Officer | P-Purchase | A | Common Stock | 6,783 | 0.74 | 5.0K | 129,366 | — | ↗ |
| 2022-12-16 | Minai-Azary Jennifer Lynn | Officer | P-Purchase | A | Common Stock | 25,000 | 0.74 | 18.5K | 40,000 | — | ↗ |
| 2022-12-16 | Lehr Martin A. | Officer | P-Purchase | A | Common Stock | 20,000 | 0.74 | 14.8K | 122,583 | — | ↗ |
| 2022-12-09 | Levit Alex C. | Officer | P-Purchase | A | Common Stock | 6,000 | 0.85 | 5.1K | 9,000 | — | ↗ |
| 2022-08-19 | Lehr Martin A. | Officer | P-Purchase | A | Common Stock | 13,000 | 1.85 | 24.1K | 102,583 | — | ↗ |
| 2022-08-17 | Minai-Azary Jennifer Lynn | Officer | P-Purchase | A | Common Stock | 15,000 | 1.80 | 27.0K | 15,000 | — | ↗ |
| 2022-08-16 | Sahmoud Tarek | Officer | P-Purchase | A | Common Stock | 10,000 | 1.95 | 19.5K | 10,000 | — | ↗ |
| 2022-08-12 | Sahmoud Tarek | Officer | A-Award | A | Stock Option (right to buy) | 25,000 | 0.00 | — | 25,000 | — | ↗ |
| 2022-06-02 | West Linda | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 2.19 | 54.8K | 25,000 | — | ↗ |
| 2022-06-02 | Stacey Jennifer Evans | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 2.19 | 54.8K | 25,000 | — | ↗ |
| 2022-06-02 | Kantoff Philip W. | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 0.00 | — | 25,000 | — | ↗ |
| 2022-06-02 | BERMAN RICHARD J | Director | A-Award | A | Stock Option (right to buy) | 50,000 | 2.19 | 109.5K | 50,000 | — | ↗ |
| 2022-02-25 | Minai-Azary Jennifer Lynn | Officer | A-Award | A | Stock Option (right to buy) | 112,470 | 1.79 | 201.3K | 112,470 | — | ↗ |
| 2022-02-25 | Levit Alex C. | Officer | A-Award | A | Stock Option (right to buy) | 107,870 | 1.79 | 193.1K | 107,870 | — | ↗ |
| 2022-02-25 | Lehr Martin A. | Director / Officer | A-Award | A | Stock Option (right to buy) | 254,300 | 1.79 | 455.2K | 254,300 | — | ↗ |
| 2022-02-15 | Rencher William F. | — | A-Award | A | Stock Option (right to buy) | 8,000 | 2.05 | 16.4K | 8,000 | — | ↗ |
| 2022-02-15 | Dick Evan G. | — | A-Award | A | Stock Option (right to buy) | 29,223 | 2.05 | 59.9K | 29,223 | — | ↗ |
| 2021-12-16 | Lehr Martin A. | Director / Officer | P-Purchase | A | Common Stock | 13,000 | 3.22 | 41.8K | 820,190 | — | ↗ |
| 2021-11-01 | Minai-Azary Jennifer Lynn | Officer | A-Award | A | Stock Option (right to buy) | 52,753 | 5.59 | 294.9K | 52,753 | — | ↗ |
| 2021-10-22 | Levit Alex C. | Officer | P-Purchase | A | Common Stock | 3,000 | 5.00 | 15.0K | 3,000 | — | ↗ |
| 2021-10-22 | Lehr Martin A. | Director / Officer | C-Conversion | D | Series Seed Preferred Stock | 586,476 | 0.00 | — | 0 | I | ↗ |
| 2021-10-22 | Dick Evan G. | Officer | C-Conversion | A | Common Stock | 26,587 | 0.00 | — | 87,139 | D | ↗ |
| 2021-10-19 | West Linda | Director | — | D | Stock Option (right to buy) | 15,000 | 4.94 | 74.1K | 0 | — | ↗ |
| 2021-10-19 | Stacey Jennifer Evans | Director | — | D | Stock Option (right to buy) | 15,000 | 4.94 | 74.1K | 0 | — | ↗ |
| 2021-10-19 | Sahmoud Tarek | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-10-19 | Rencher William F. | Officer | — | D | Stock Option (right to buy) | 12,333 | 16.92 | 208.7K | 0 | — | ↗ |
| 2021-10-19 | Levit Alex C. | Officer | — | D | Stock Option (right to buy) | 833 | 5.70 | 4.7K | 0 | — | ↗ |
| 2021-10-19 | Lehr Martin A. | Director / Officer | — | I | Series Seed Preferred Stock | 586,476 | 0.00 | — | 0 | — | ↗ |
| 2021-10-19 | Kantoff Philip W. | Director | — | D | Common Stock | 0 | 0.00 | — | 3,533 | — | ↗ |
| 2021-10-19 | Dick Evan G. | Officer | — | D | Series Seed Preferred Stock | 26,587 | 0.00 | — | 0 | — | ↗ |
| 2021-10-19 | BERMAN RICHARD J | Director | — | D | Stock Option (right to buy) | 30,000 | 4.94 | 148.2K | 0 | — | ↗ |
| 2020-12-20 | Lehr Martin A. | Director / Officer | — | I | Warrant (right to buy) | 52,680 | 7.14 | 376.1K | 0 | — | ↗ |
Executive team
Top executives
Shares Outstanding
91.88M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Martin Lehr Chief Executive Officer | 588.5K | 15.0K | — | 551.4K | 300.0K | 10.5K | 1.47M | 37.63% | ↗ |
| 2 | 2025 | Jennifer Minai-Azary Chief Financial Officer and Treasurer | 421.7K | 8.5K | — | 255.4K | 170.0K | 10.5K | 866.1K | 29.49% | ↗ |
| 3 | 2025 | Alex Levit Chief Legal Officer and Corporate Secretary | 397.8K | 8.0K | — | 240.4K | 160.0K | 10.5K | 816.7K | 29.43% | ↗ |
| 4 | 2024 | Martin Lehr Chief Executive Officer | 506.3K | 10.2K | — | 245.5K | 238.8K | 10.4K | 1.01M | 24.28% | ↗ |
| 5 | 2024 | Jennifer Minai-Azary Chief Financial Officer | 397.4K | 6.4K | — | 134.9K | 150.0K | 10.4K | 699.0K | 19.30% | ↗ |
| 6 | 2024 | Jennifer Minai-Azary Chief Financial Officer and Treasurer | 397.4K | 6.4K | — | 134.9K | 150.0K | 10.4K | 699.0K | 19.30% | ↗ |
| 7 | 2024 | Alex Levit Chief Legal Officer and Corporate Secretary | 381.1K | 6.1K | — | 129.3K | 143.8K | 10.4K | 670.7K | 19.28% | ↗ |
| 8 | 2024 | Alex Levit Chief Legal Officer | 381.1K | 6.1K | — | 129.3K | 143.8K | 10.4K | 670.7K | 19.28% | ↗ |
| 9 | 2023 | Martin Lehr Chief Executive Officer | 491.5K | — | — | 186.6K | 172.7K | 9.9K | 860.7K | 21.68% | ↗ |
| 10 | 2023 | Jennifer Minai-Azary Chief Financial Officer | 385.8K | — | — | 102.5K | 108.4K | 9.9K | 606.7K | 16.90% | ↗ |
| 11 | 2023 | Alex Levit Chief Legal Officer | 370.0K | — | — | 98.3K | 104.0K | 9.9K | 582.1K | 16.89% | ↗ |
| 12 | 2022 | Martin Lehr Chief Executive Officer | 476.6K | 35.9K | — | 332.4K | 203.6K | 9.2K | 1.06M | 31.43% | ↗ |
| 13 | 2022 | Jennifer Minai-Azary Chief Financial Officer | 374.1K | 22.6K | — | 147.0K | 127.8K | 9.2K | 680.7K | 21.60% | ↗ |
| 14 | 2022 | Alex Levit Chief Legal Officer | 358.8K | 21.6K | — | 141.0K | 122.6K | 9.2K | 653.1K | 21.59% | ↗ |
| 15 | 2021 | Martin Lehr Chief Executive Officer | 291.2K | — | — | 1.06M | 232.5K | — | 1.59M | 67.02% | ↗ |
| 16 | 2021 | Alex Levit Chief Legal Officer | 257.2K | — | — | 199.5K | 140.0K | — | 596.7K | 33.44% | ↗ |
| 17 | 2021 | Jennifer Minai-Azary Chief Financial Officer | 60.8K | 15.0K | — | 222.0K | 24.3K | — | 322.2K | 68.91% | ↗ |
| 18 | 2020 | Martin Lehr Chief Executive Officer | 250.0K | — | — | — | — | — | 250.0K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Martin A. Lehr | Co-Founder, President, Chief Executive Officer & Director | 914.0K | male |
| Jennifer Minai-Azary | Chief Financial Officer & Treasurer | 610.7K | female |
| Alex C. Levit | Chief Legal Officer & Corporate Secretary | 576.3K | male |
| Karen Chagin | Chief Medical Officer | 26.6K | — |
| Jennifer Dashnau | Senior Vice President of Technical Operations | — | female |
| Christopher Beck | Senior Vice President of Operations | — | male |
| Jeffrey Liebman | Associate Director of Accounting | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for CNTX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
